CTRI/2024/05/066650
Not yet recruiting
Phase 3
Three arm clinical study to evaluate the efficacy of sidharthak raskriya topically siddharthak kashaya orally and both combined together in ekkustha with special reference to psoriasis - NI
Dr abhijeet sureshrao bhendekar0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: L858- Other specified epidermal thickening
- Sponsor
- Dr abhijeet sureshrao bhendekar
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with clinical features of eka\-kustha having signs and symptoms namely kandu ( itching), shushkta, vaivarnya( depigmentation), mastyashakalopama( silvery patch skin)
- •patients of both gender male and female, irrespective of of caste and sccioeconomic status.
Exclusion Criteria
- •Patient suffering from any chronic skin disease, immmune suppressed systemic disorder.
- •patient suffering from any other systemic disorder like tuberculosis, diabetes mellitus , HBsAg positive and know case of leprosy.
- •pregnant and lactating woman
- •Psoriatic arthritis.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-DKovartis Pharma Services AG124
Active, not recruiting
Phase 1
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-DEovartis Pharma Services AG124
Active, not recruiting
Phase 1
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-ESovartis Farmacéutica S.A.105
Active, not recruiting
Phase 1
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-SEovartis Pharma Services AG124
Active, not recruiting
Phase 1
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-ITOVARTIS FARMA124